654 related articles for article (PubMed ID: 34441055)
61. A comparison of performance of 6-mononucleotide site panel and NCI panel for microsatellite instability detection in patients with colorectal adenocarcinoma.
He L; Yang J; Zhang B; Wang Y; Wang J; Ye Q
Pathol Res Pract; 2023 Apr; 244():154390. PubMed ID: 36905693
[TBL] [Abstract][Full Text] [Related]
62. Microsatellite Status Detection in Gastrointestinal Cancers: PCR/NGS Is Mandatory in Negative/Patchy MMR Immunohistochemistry.
Zito Marino F; Amato M; Ronchi A; Panarese I; Ferraraccio F; De Vita F; Tirino G; Martinelli E; Troiani T; Facchini G; Pirozzi F; Perrotta M; Incoronato P; Addeo R; Selvaggi F; Lucido FS; Caraglia M; Savarese G; Sirica R; Casillo M; Lieto E; Auricchio A; Cardella F; Docimo L; Galizia G; Franco R
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565332
[TBL] [Abstract][Full Text] [Related]
63. Concordance in detection of microsatellite instability by PCR and NGS in routinely processed tumor specimens of several cancer types.
Bartels S; Grote I; Wagner M; Boog J; Schipper E; Reineke-Plaass T; Kreipe H; Lehmann U
Cancer Med; 2023 Aug; 12(16):16707-16715. PubMed ID: 37376830
[TBL] [Abstract][Full Text] [Related]
64. Microsatellite instability and novel mismatch repair gene mutations in northern Chinese population with hereditary non-polyposis colorectal cancer.
Sheng JQ; Chan TL; Chan YW; Huang JS; Chen JG; Zhang MZ; Guo XL; Mu H; Chan AS; Li SR; Yuen ST; Leung SY
Chin J Dig Dis; 2006; 7(4):197-205. PubMed ID: 17054581
[TBL] [Abstract][Full Text] [Related]
65. Low prevalence of biliary tract cancer with defective mismatch repair genes in a Japanese hospital-based population.
Ando Y; Kumamoto K; Matsukawa H; Ishikawa R; Suto H; Oshima M; Kamada H; Morishita A; Kobara H; Matsunaga T; Haba R; Masaki T; Suzuki Y; Okano K
Oncol Lett; 2022 Jan; 23(1):4. PubMed ID: 34820003
[TBL] [Abstract][Full Text] [Related]
66. Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer.
Inamori K; Togashi Y; Fukuoka S; Akagi K; Ogasawara K; Irie T; Motooka D; Kobayashi Y; Sugiyama D; Kojima M; Shiiya N; Nakamura S; Maruyama S; Suzuki Y; Ito M; Nishikawa H
JCI Insight; 2021 May; 6(9):. PubMed ID: 33755600
[TBL] [Abstract][Full Text] [Related]
67. Application of immune checkpoint inhibitors in colorectal cancer.
Wang L; Huang C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 46(8):894-899. PubMed ID: 34565736
[TBL] [Abstract][Full Text] [Related]
68. Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain.
Garcia-Carbonero R; González Astorga B; Vidal Tocino R; Contreras Toledo D; Pericay C; Fernández Montes A; Falcó E; González Cordero M; Reina Zoilo JJ; Alonso V; Rodríguez Salas N; Gil-Raga M; Santos C; Páez D; Anton-Pascual B; Aguilar F; Morales P
Clin Transl Oncol; 2024 Apr; 26(4):864-871. PubMed ID: 37651021
[TBL] [Abstract][Full Text] [Related]
69. MSI/MMR-deficient tumor diagnosis: Which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: Differences between tumors.
Svrcek M; Lascols O; Cohen R; Collura A; Jonchère V; Fléjou JF; Buhard O; Duval A
Bull Cancer; 2019 Feb; 106(2):119-128. PubMed ID: 30713006
[TBL] [Abstract][Full Text] [Related]
70. Clinicopathological characteristics of high microsatellite instability/mismatch repair-deficient colorectal cancer: A narrative review.
Mei WJ; Mi M; Qian J; Xiao N; Yuan Y; Ding PR
Front Immunol; 2022; 13():1019582. PubMed ID: 36618386
[TBL] [Abstract][Full Text] [Related]
71. Homogeneous MMR Deficiency Throughout the Entire Tumor Mass Occurs in a Subset of Colorectal Neuroendocrine Carcinomas.
Fraune C; Simon R; Hube-Magg C; Makrypidi-Fraune G; Kluth M; Büscheck F; Amin T; Viol F; Fehrle W; Dum D; Höflmayer D; Burandt E; Clauditz TS; Perez D; Izbicki J; Wilczak W; Sauter G; Steurer S; Schrader J
Endocr Pathol; 2020 Jun; 31(2):182-189. PubMed ID: 32144630
[TBL] [Abstract][Full Text] [Related]
72. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors.
Salem ME; Bodor JN; Puccini A; Xiu J; Goldberg RM; Grothey A; Korn WM; Shields AF; Worrilow WM; Kim ES; Lenz HJ; Marshall JL; Hall MJ
Int J Cancer; 2020 Nov; 147(10):2948-2956. PubMed ID: 32449172
[TBL] [Abstract][Full Text] [Related]
73. The Clinical Significance of Microsatellite Instability in Precision Treatment.
Huang Z; Chen X; Liu C; Cui L
Methods Mol Biol; 2020; 2204():33-38. PubMed ID: 32710312
[TBL] [Abstract][Full Text] [Related]
74. Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer.
Morse MA; Overman MJ; Hartman L; Khoukaz T; Brutcher E; Lenz HJ; Atasoy A; Shangguan T; Zhao H; El-Rayes B
Oncologist; 2019 Nov; 24(11):1453-1461. PubMed ID: 31147488
[TBL] [Abstract][Full Text] [Related]
75. Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer.
Guyot D'Asnières De Salins A; Tachon G; Cohen R; Karayan-Tapon L; Junca A; Frouin E; Godet J; Evrard C; Randrian V; Duval A; Svrcek M; Lascols O; Vignot S; Coulet F; André T; Fléjou JF; Cervera P; Tougeron D
ESMO Open; 2021 Jun; 6(3):100120. PubMed ID: 33930657
[TBL] [Abstract][Full Text] [Related]
76. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
77. Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune Microenvironment.
Song Y; Gu Y; Hu X; Wang M; He Q; Li Y
Onco Targets Ther; 2021; 14():4485-4497. PubMed ID: 34429613
[TBL] [Abstract][Full Text] [Related]
78. Artificial intelligence for detection of microsatellite instability in colorectal cancer-a multicentric analysis of a pre-screening tool for clinical application.
Echle A; Ghaffari Laleh N; Quirke P; Grabsch HI; Muti HS; Saldanha OL; Brockmoeller SF; van den Brandt PA; Hutchins GGA; Richman SD; Horisberger K; Galata C; Ebert MP; Eckardt M; Boutros M; Horst D; Reissfelder C; Alwers E; Brinker TJ; Langer R; Jenniskens JCA; Offermans K; Mueller W; Gray R; Gruber SB; Greenson JK; Rennert G; Bonner JD; Schmolze D; Chang-Claude J; Brenner H; Trautwein C; Boor P; Jaeger D; Gaisa NT; Hoffmeister M; West NP; Kather JN
ESMO Open; 2022 Apr; 7(2):100400. PubMed ID: 35247870
[TBL] [Abstract][Full Text] [Related]
79. High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer.
Möller K; Blessin NC; Höflmayer D; Büscheck F; Luebke AM; Kluth M; Hube-Magg C; Zalewski K; Hinsch A; Neipp M; Mofid H; Lárusson H; Daniels T; Isbert C; Coerper S; Ditterich D; Rupprecht H; Goetz A; Bernreuther C; Sauter G; Uhlig R; Wilczak W; Simon R; Steurer S; Minner S; Burandt E; Krech T; Perez D; Izbicki JR; Clauditz TS; Marx AH
Acta Oncol; 2021 Sep; 60(9):1210-1217. PubMed ID: 34092167
[TBL] [Abstract][Full Text] [Related]
80. Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update.
Boukouris AE; Theochari M; Stefanou D; Papalambros A; Felekouras E; Gogas H; Ziogas DC
Crit Rev Oncol Hematol; 2022 May; 173():103663. PubMed ID: 35351582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
